244 related articles for article (PubMed ID: 32039480)
1. Post-haematopoietic cell transplantation outcomes: why ST2 became a 'golden nugget' biomarker.
Paczesny S
Br J Haematol; 2021 Mar; 192(6):951-967. PubMed ID: 32039480
[TBL] [Abstract][Full Text] [Related]
2. Predictive Values of Early Suppression of Tumorigenicity 2 for Acute GVHD and Transplant-related Complications after Allogeneic Stem Cell Transplantation: Prospective Observational Study.
Matsumura A; Miyazaki T; Tachibana T; Ando T; Koyama M; Koyama S; Ishii Y; Takahashi H; Nakajima Y; Numata A; Yamamoto W; Motohashi K; Hagihara M; Matsumoto K; Fujisawa S; Nakajima H
Turk J Haematol; 2020 Feb; 37(1):20-29. PubMed ID: 31464120
[TBL] [Abstract][Full Text] [Related]
3. Assessment of ST2 and Reg3a levels in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Aladağ Karakulak E; Demİroğlu H; Malkan UY; Akman U; Göker H; Büyükaşik Y
Turk J Med Sci; 2021 Feb; 51(1):355-358. PubMed ID: 32927932
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Systemic biomarkers of allogeneic haematopoietic stem cell transplantation outcome-Brief introduction.
Mrazek F
HLA; 2019 Dec; 94 Suppl 2():25-29. PubMed ID: 31729192
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for posttransplantation outcomes.
Paczesny S
Blood; 2018 May; 131(20):2193-2204. PubMed ID: 29622549
[TBL] [Abstract][Full Text] [Related]
7. Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups.
Rowan CM; Pike F; Cooke KR; Krance R; Carpenter PA; Duncan C; Jacobsohn DA; Bollard CM; Cruz CRY; Malatpure A; Farag SS; Renbarger J; Liu H; Bakoyannis G; Hanash S; Paczesny S
Blood; 2020 Apr; 135(17):1428-1437. PubMed ID: 31972009
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers for Allogeneic HCT Outcomes.
Adom D; Rowan C; Adeniyan T; Yang J; Paczesny S
Front Immunol; 2020; 11():673. PubMed ID: 32373125
[TBL] [Abstract][Full Text] [Related]
9. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.
Vander Lugt MT; Braun TM; Hanash S; Ritz J; Ho VT; Antin JH; Zhang Q; Wong CH; Wang H; Chin A; Gomez A; Harris AC; Levine JE; Choi SW; Couriel D; Reddy P; Ferrara JL; Paczesny S
N Engl J Med; 2013 Aug; 369(6):529-39. PubMed ID: 23924003
[TBL] [Abstract][Full Text] [Related]
10. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
[TBL] [Abstract][Full Text] [Related]
11. Multiple functional variants in the
Karaesmen E; Hahn T; Dile AJ; Rizvi AA; Wang J; Wang T; Haagenson MD; Preus L; Zhu Q; Liu Q; Yan L; Liu S; Haiman CA; Stram D; Pooler L; Sheng X; Van Den Berg D; Brock G; Webb A; McCarthy PL; Pasquini MC; Spellman SR; Lee SJ; Paczesny S; Sucheston-Campbell LE
Blood Adv; 2019 Aug; 3(16):2512-2524. PubMed ID: 31455667
[TBL] [Abstract][Full Text] [Related]
12. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD.
Qayed M; Kapoor U; Gillespie S; Westbrook A; Aguayo-Hiraldo P; Ayuk FA; Aziz M; Baez J; Choe H; DeFilipp Z; Etra A; Grupp SA; Hexner E; Holler E; Hogan WJ; Kowalyk S; Merli P; Morales G; Nakamura R; Pulsipher MA; Schechter T; Shah J; Spyrou N; Srinagesh HK; Wölfl M; Yanik G; Young R; Kitko CL; Ferrara JLM; Levine JE
Transplant Cell Ther; 2024 Jun; 30(6):603.e1-603.e11. PubMed ID: 38548227
[TBL] [Abstract][Full Text] [Related]
13. Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease.
McDonald GB; Tabellini L; Storer BE; Martin PJ; Lawler RL; Rosinski SL; Schoch HG; Hansen JA
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1257-1263. PubMed ID: 28478120
[TBL] [Abstract][Full Text] [Related]
14. Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.
Dander E; De Lorenzo P; Bottazzi B; Quarello P; Vinci P; Balduzzi A; Masciocchi F; Bonanomi S; Cappuzzello C; Prunotto G; Pavan F; Pasqualini F; Sironi M; Cuccovillo I; Leone R; Salvatori G; Parma M; Terruzzi E; Pagni F; Locatelli F; Mantovani A; Fagioli F; Biondi A; Garlanda C; Valsecchi MG; Rovelli A; D'Amico G
Oncotarget; 2016 Dec; 7(50):82123-82138. PubMed ID: 27893415
[TBL] [Abstract][Full Text] [Related]
15. ST2 and REG3α as Predictive Biomarkers After Haploidentical Stem Cell Transplantation Using Post-transplantation High-Dose Cyclophosphamide.
Solán L; Kwon M; Carbonell D; Dorado N; Balsalobre P; Serrano D; Chicano-Lavilla M; Anguita J; Gayoso J; Díez-Martín JL; Martínez-Laperche C; Buño I
Front Immunol; 2019; 10():2338. PubMed ID: 31649665
[TBL] [Abstract][Full Text] [Related]
16. Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide.
Kanakry CG; Bakoyannis G; Perkins SM; McCurdy SR; Vulic A; Warren EH; Daguindau E; Olmsted T; Mumaw C; Towlerton AMH; Cooke KR; O'Donnell PV; Symons HJ; Paczesny S; Luznik L
Haematologica; 2017 May; 102(5):932-940. PubMed ID: 28126963
[TBL] [Abstract][Full Text] [Related]
17. Clinical Proteomics for Post-Hematopoeitic Stem Cell Transplantation Outcomes.
Paczesny S; Metzger J
Proteomics Clin Appl; 2019 Mar; 13(2):e1800145. PubMed ID: 30307119
[TBL] [Abstract][Full Text] [Related]
18. Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall Survival.
Kordelas L; Buttkereit U; Heinemann FM; Horn PA; Giebel B; Beelen DW; Reinhardt HC; Rebmann V
Front Immunol; 2021; 12():694843. PubMed ID: 34630383
[TBL] [Abstract][Full Text] [Related]
19. The IL-33/ST2 axis augments effector T-cell responses during acute GVHD.
Reichenbach DK; Schwarze V; Matta BM; Tkachev V; Lieberknecht E; Liu Q; Koehn BH; Pfeifer D; Taylor PA; Prinz G; Dierbach H; Stickel N; Beck Y; Warncke M; Junt T; Schmitt-Graeff A; Nakae S; Follo M; Wertheimer T; Schwab L; Devlin J; Watkins SC; Duyster J; Ferrara JL; Turnquist HR; Zeiser R; Blazar BR
Blood; 2015 May; 125(20):3183-92. PubMed ID: 25814531
[TBL] [Abstract][Full Text] [Related]
20. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.
Hartwell MJ; Özbek U; Holler E; Renteria AS; Major-Monfried H; Reddy P; Aziz M; Hogan WJ; Ayuk F; Efebera YA; Hexner EO; Bunworasate U; Qayed M; Ordemann R; Wölfl M; Mielke S; Pawarode A; Chen YB; Devine S; Harris AC; Jagasia M; Kitko CL; Litzow MR; Kröger N; Locatelli F; Morales G; Nakamura R; Reshef R; Rösler W; Weber D; Wudhikarn K; Yanik GA; Levine JE; Ferrara JL
JCI Insight; 2017 Feb; 2(3):e89798. PubMed ID: 28194439
[No Abstract] [Full Text] [Related]
[Next] [New Search]
